Elsevier

Toxicology

Volume 50, Issue 1, June 1988, Pages 1-26
Toxicology

Review paper
Aspartame: Review of recent experimental and observational data

https://doi.org/10.1016/0300-483X(88)90117-5Get rights and content

Abstract

In this report the neurotoxicity of aspartame and its constituent amino acids aspartic acid and phenylalanine is reviewed. The adverse reactions ascribed to the consumption of aspartame-containing products, as reported in the U.S.A., are discussed and placed in perspevtive with the results of recent behavioural studies in humans and animals. The issue of common intake levels associated with proposed uses of aspartame is addressed.

In brief, the following conclusions can be drawn: When aspartame is consumed at levels within the ADI-limit of 40 mg/kg body wt, there is no significant risk for an aspartate-induced neurotoxic effect in the brain. When aspartame is consumed at levels within the ADI-limit by normal subjects or persons heterozygous for phenylketonuria (PKU) the resultant plasma phenylalanine concentrations are practically always within the normal post-prandial range; elevation to plasma concentrations commonly associated with adverse effects has not been observed. Persons suffering from phenylketonuria (PKU-homozygotes) on a phenylalanine-restricted diet should avoid consumption of aspartame. PKU-homozygotes on the (less strict) phenylalanine-liberalised diet should be made aware of the phenylalanine content of aspartame. In the available behavioural studies in humans with acute dosing, no adverse effects were observed. Long-term studies on behaviour and cognitive function in (sensitive) humans are lacking. Analyses of adverse reaction reports made by consumers in the U.S.A. have not yielded a specific constellation of symptoms clearly related to aspartame that would suggest a widespread public health hazard associated with aspartame use. Focussed clinical studies are now being carried out in the U.S.A.; the results should provide additional evidence concerning the interpretation of the reports on adverse reactions ascribed to aspartame. In the regulation of admitted uses for aspartame the possibility of intake levels exceeding the ADI-limit in some groups of consumers should be a point of attention.

References (86)

  • M. Ryan-Harshman et al.

    Phenylalanine and aspartame fail to alter feeding behavior, mood and arousal in men

    Physiol. Behav.

    (1987)
  • G.E. Inglett

    Sweeteners: an overall perspective

  • JECFA - Joint FAO/WHO Expert Committee on Food Addtitives

    Toxicological evaluation of certain food additives

    WHO Food Additives Series No. 15

    (1980)
  • T.R. Tephly et al.

    Methanol metabolism and toxicity

  • L.D. Stegink

    Aspartate and glutamate metabolism

  • W.M. Pardridge

    Potential effects of the dipeptide sweetener aspartame on the brain

  • A.E. Applebaum et al.

    Aspartate-induced neurotoxicity in infant mice

  • J.W. Olney et al.

    Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine

    Nature

    (1970)
  • W.M. Pardridge

    Regulation of amino acid availability to brain: selective control mechanisms for glutamate

  • L.D. Stegink et al.

    Comparative metabolism of glutamate in the mouse, monkey and man

  • L.D. Stegink et al.

    Factors affecting plasma glutamate levels in normal adult subjects

  • L.D. Stegink et al.

    Monosodium glutamate metabolism in the neonatal monkey

    Am. J. Physiol.

    (1975)
  • S. Garattini

    Evaluation of the neurotoxic effects of glutamic acid

  • IGTC-International Glutamate Technical Committee, Scientific literature review on glutamates, Report dated September...
  • A. Okaniwa et al.

    Histopathological study on effects of potassium aspartate on the hypothalamus of rats

    J. Toxicol. Sci.

    (1979)
  • J.W. Olney et al.

    Glutamate-induced brain damage in infant primates

    J. Neuropathol. Exp. Neurol.

    (1972)
  • R. Abraham et al.

    The response of the hypothalamus to high doses of monosodium glutamate in mice and monkeys

    Toxicol. Appl. Pharmacol.

    (1971)
  • R. Heywood et al.

    The effect of oral administration of monosodium glutamate on premature Rhesus monkeys

    Huntingdon Research Centre Report No. 36/75994

    (1975)
  • W.A. Reynolds et al.

    Hypothalamic morphology following ingestion of aspartame or MSG in the neonatal rodent and primate: A preliminary report

    J. Toxicol. Environ. Health

    (1976)
  • W.A. Reynolds et al.

    Morphology of the fetal monkey hypothalamus after in utero exposure to monosodium glutamate

  • W.A. Reynolds et al.

    Monosodium glutamate: Absence of hypothalamic lesions after ingestion by newborn primates

    Science

    (1971)
  • W.A. Reynolds et al.

    Neuropathology studies following aspartame ingestion by infant non-human primates

  • L.D. Stegink

    Aspartame metabolism in humans: acute dosing studies

  • L.D. Stegink et al.

    Effect of aspartame-loading upon plasma and erythrocyte free amino acid levels and blood methanol levels in normal one-year old children

    Report to General Foods Corporation Tarrytown

    (1978)
  • L.J. Filer et al.

    Aspartame ingestion by human infants

  • R.M. Pitkin et al.

    Glutamate metabolism and placental transfer in pregnancy

  • G.L. Baker

    Aspartame ingestion during lactation

  • R.M. Pitkin

    Aspartame ingestion during pregnancy

  • A.E. Harper

    Phenylalanine metabolism

  • M.B. Krassner

    Diet and brain function

    Nutr. Rev.

    (May 1986)
  • Q.R. smith

    Kinetic analysis of neutral amino acid transport across the blood brain barrier

  • J.D. Fernstrom

    Effects of aspartame on large neutral amino acids and monoamine neurotransmitters in the rat brain

  • S. Kaufman

    The enzymology of phenylketonuria

  • Cited by (0)

    Project No. 86/678606/005 and 86/678608/010.

    View full text